- Home
- IONS vs RITM Comparison
IONS vs RITM Comparison
Compare IONS & RITM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IONS
- RITM
- Stock Information
- Founded
- IONS 1989
- RITM 2011
- Country
- IONS United States
- RITM United States
- Employees
- IONS N/A
- RITM N/A
- Industry
- IONS Biotechnology: Pharmaceutical Preparations
- RITM Real Estate Investment Trusts
- Sector
- IONS Health Care
- RITM Real Estate
- Exchange
- IONS Nasdaq
- RITM Nasdaq
- Market Cap
- IONS 6.0B
- RITM 5.7B
- IPO Year
- IONS 1991
- RITM N/A
- Fundamental
- Price
- IONS $31.43
- RITM $11.34
- Analyst Decision
- IONS Buy
- RITM Strong Buy
- Analyst Count
- IONS 18
- RITM 9
- Target Price
- IONS $62.00
- RITM $12.78
- AVG Volume (30 Days)
- IONS 1.5M
- RITM 4.1M
- Earning Date
- IONS 02-19-2025
- RITM 02-05-2025
- Dividend Yield
- IONS N/A
- RITM 8.81%
- EPS Growth
- IONS N/A
- RITM N/A
- EPS
- IONS N/A
- RITM 0.99
- Revenue
- IONS $803,067,000.00
- RITM $3,006,456,000.00
- Revenue This Year
- IONS N/A
- RITM N/A
- Revenue Next Year
- IONS $10.85
- RITM $4.32
- P/E Ratio
- IONS N/A
- RITM $11.50
- Revenue Growth
- IONS 30.57
- RITM 1.78
- 52 Week Low
- IONS $31.41
- RITM $9.97
- 52 Week High
- IONS $52.49
- RITM $12.02
- Technical
- Relative Strength Index (RSI)
- IONS 33.19
- RITM 62.00
- Support Level
- IONS $32.61
- RITM $10.48
- Resistance Level
- IONS $35.37
- RITM $11.21
- Average True Range (ATR)
- IONS 1.28
- RITM 0.18
- MACD
- IONS -0.30
- RITM 0.04
- Stochastic Oscillator
- IONS 0.36
- RITM 96.63
About IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024.
About RITM Rithm Capital Corp.
Rithm Capital Corp operates as a real estate investment trust that provides capital and services to the real estate and financial services industries. The company's mission is to generate attractive risk-adjusted returns in all interest-rate environments through a complementary portfolio of investments and operating businesses. Rithm Capital's investment portfolio is composed of mortgage servicing-related assets (full and excess MSRs and servicer advances), residential securities (and associated call rights) loans (including single-family rental), and consumer loans.